BeOne Medicines company profile
Company profile
BeOne Medicines has 12,000 employees and is headquartered in Basel, Switzerland.
BRUKINSA and TEVIMBRA are the medicines most closely associated with BeOne Medicines AG, which was known as BeiGene until its renaming in May 2025. BRUKINSA, a BTK inhibitor, is used against several blood cancers, while TEVIMBRA is an anti-PD-1 antibody that treats solid tumors and blood cancers. The pipeline includes candidates such as sonrotoclax, a Bcl-2 inhibitor, and zanidatamab, a HER2-targeted bispecific antibody. Partners include Amgen, BMS, Novartis and Luye Pharmaceutical, and the company holds an agreement with the U.S. government on access to cancer medicines.
In the fiscal year ended December 2025, revenue reached 5.3 billion USD, up 40.2% from the previous year, and net income was 286.9 million USD. The United States accounted for 53.9% of revenue and China for 31.4%, with Europe at 11.4%. The company had 12,000 employees and is headquartered in Basel, Switzerland. Its shares are also listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 94 Aeschengraben 27, 4051, Basel
- Employees
- 12,000
- Chief executive
- John Oyler
- Founded
- 2010
- Fiscal year
- January - December
- Listing
- ONC · NASDAQ
- Currency
- USD
- ISIN
- US07725L1026
- Website
- beonemedicines.com
BeOne Medicines and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| BeOne MedicinesONC | United States | $46.98B | 12,000 | 17.8% | 52.7 |
| Royalty PharmaRPRX | United States | $39.4B | 100 | 64.4% | 45.4 |
| Revolution MedicinesRVMD | United States | $37.27B | 883 | -853.0% | — |
| argenxARGX | United States | $59.8B | 1,863 | 31.9% | 32.9 |
| Roivant SciencesROIV | United States | $28.64B | 721 | -3,226.3% | — |
| InsmedINSM | United States | $26.96B | 1,664 | -41.7% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
